CHRS at a glance
Coherus Oncology, Inc. (CHRS, SEC CIK 1512762) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as June 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Coherus Oncology, Inc. (CHRS) reported revenue of $42.2 million (down 84.2% from FY2024) and net income of $168.0 million. Diluted EPS was $1.43.
- As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Coherus Oncology, Inc. (CHRS) shares worth $32.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $42.2M
- −84.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 22 funds
- $32.7M · +0 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $14.3M, up $2.7M YoY from $11.6M, driven by LOQTORZI volume growth
- LOQTORZI best-performing product: revenue $14.0M vs $11.2M YoY
- Gross margin figures not disclosed; operating profitability pressured by $3.4M debt extinguishment loss
- Cash and investments $83.6M vs $172.1M at December 31, 2025; operating cash use $154.0M
- 2026 revenue expected higher, but substantial doubt remains about continuing as a going concern within one year
Risk Factors
- Newly emphasized going-concern risk: $83.6 million liquidity and $1.5 billion accumulated deficit after UDENYCA divestiture
- Commercial risk: LOQTORZI faces penpulimab competition following its April 2025 FDA approval for nasopharyngeal carcinoma
- Regulatory risk: OBBBA Medicaid funding reductions could reduce LOQTORZI sales through lower enrollment and coverage
- Operational risk: U.S. onshoring of LOQTORZI, casdozokitug and tagmokitug manufacturing may face approval delays
- Financial risk: UDENYCA earnouts are uncertain, with $37.5 million payments tied to $300 million and $350 million sales thresholds
AI summary of the CHRS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Press release furnished as Exhibit 99.1, containing detailed financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q3 revenue $14.3M, up from $11.6M, while LOQTORZI revenue reached $14.0M, up 25% year over year
- Strategic reset prioritizes tagmokitug/toripalimab in esophageal cancer, while deprioritizing other indications
Item 8.01: Other Events
- Tagmokitug showed strongest signal in first-line ESCC: post-cutoff cORR 89% (8/9), including 100% in PD-L1-positive patients
- Second-line ESCC 700 mg arm: 16.7% cORR, 33.3% CBR and 5.5-month mPFS versus ~3.4-month chemotherapy benchmark
Item EX-99.1: Item EX-99.1
- Tagmokitug first-line ESCC data strengthened development case: cORR 75% across PD-L1 status and 100% in PD-L1-positive patients
- Post-cutoff cORR increased to 89% (8/9), but based on a very small, early-stage efficacy dataset
Item 7.01: Regulation FD Disclosure
- Interim clinical data announced from TREGCHECK™ program evaluating tagmokitug in combination with toripalimab
- Study includes regimens with or without chemotherapy
Item 8.01: Other Events
- At-the-market equity facility enabling up to $50.0 million in common-stock sales
- No obligation to issue shares, preserving financing flexibility but creating potential dilution
AI summaries of CHRS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CHRS
Don't miss the next CHRS filing
- Alerts as it files. A push when CHRS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CHRS, by share count.
- Ask anything. An AI agent that reads every CHRS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Newcomer Lee Nisley | A | Jun 5, 2026 | 60,000 | - |
| Karachun Rita A | A | Jun 5, 2026 | 60,000 | - |
| Wahlstrom Mats | A | Jun 5, 2026 | 30,000 | - |
| Wahlstrom Mats | A | Jun 5, 2026 | 60,000 | - |
| Ryan Michael Lee | A | Jun 5, 2026 | 60,000 | - |
| O'Donnell-Tormey Jill | A | Jun 5, 2026 | 60,000 | - |
| Newton Charles W. | A | Jun 5, 2026 | 60,000 | - |
| O'Donnell-Tormey Jill | A | Jun 5, 2026 | 30,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $267.0M | $42.2M |
| Operating Income | -$203.2M | -$111.7M | -$181.1M |
| Net Income | -$237.9M | $28.5M | $168.0M |
| Op. Margin | - | -41.8% | -429.5% |
| Net Margin | - | 10.7% | 398.4% |
| Balance Sheet | |||
| Total Assets | $629.6M | $448.5M | $258.3M |
| Equity | -$193.4M | -$132.0M | $61.0M |
| ROE | 123.0% | -21.6% | 275.4% |
| Per Share | |||
| EPS | $-2.53 | $0.25 | $1.43 |
| Cash Flow | |||
| Operating CF | - | -$20.4M | -$138.5M |
| CapEx | $286K | - | - |
Source: XBRL data in Coherus Oncology, Inc. (CHRS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CHRS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 22 | $32.7M |
| Q2 2026 | 22 | $40.3M |
| Q1 2026 | 22 | $44.2M |
| Q4 2025 | 20 | $39.4M |
| Q3 2025 | 19 | $44.8M |
| Q2 2025 | 20 | $21.7M |
| Q1 2025 | 18 | $16.4M |
| Q4 2024 | 14 | $24.3M |
- Goldman Sachs Group+1.39M (+231%)
- Renaissance Technologies LLC+378.8K (+67%)
- Citadel Advisors LLC+240.1K (+570%)
- Millennium Management+175.6K (+846%)
- Bank of America Corp+121.7K (+40%)
- AQR Capital Management−1.11M (-84%)
- Vanguard Capital Management LLC−351.2K (-6%)
- BlackRock−261.3K (-2%)
- Northern Trust−110.7K (-10%)
- Wells Fargo & Co−83.4K (-74%)
- Raymond James Financial+27.1K
- StoneX Group Inc.+13.5K
- Two Sigma Investments−2.26M
- FMR LLC (Fidelity)−7.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 157 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CHRS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 8-K | Aug 28, 2026 | - | Analysis | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 27, 2026 | - | - | |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-K | Mar 9, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 9, 2026 | - | Analysis | - |
| 8-K | Feb 17, 2026 | - | - | |
| SC 13G | Feb 5, 2026 | - | - | |
| 8-K | Feb 4, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
CHRS SEC filings: frequently asked questions
Which institutions hold CHRS stock?
As of September 30, 2026, the largest Coherus Oncology, Inc. (CHRS) holders among the 13F filers tracked by SignalX were BlackRock ($14.2 million), Vanguard Capital Management LLC ($6.8 million), State Street Corp ($2.9 million), Goldman Sachs Group ($2.4 million), Northern Trust ($1.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CHRS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Coherus Oncology, Inc. (CHRS) reported revenue of $42.2 million (down 84.2% from FY2024) and net income of $168.0 million. Diluted EPS was $1.43. The figures come from the XBRL data in the 10-K.
What did CHRS report in its latest 8-K?
Coherus Oncology, Inc. (CHRS) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.
What are the latest CHRS SEC filings?
Coherus Oncology, Inc. (CHRS) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on June 9, 2026.
What is CHRS's SEC CIK number?
Coherus Oncology, Inc. (CHRS)'s SEC Central Index Key (CIK) is 1512762. EDGAR lists every CHRS filing under that number.
Ask anything about CHRS
The research agent reads CHRS's filings, financials, insider trades and 13F holders, then answers with sources.